Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

Philadelphia, Pennsylvania, Oxford, United Kingdom, and Cambridge, Massachusetts–(Newsfile Corp. – March 6, 2023) – Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. (NASDAQ: TCRR), today announced entry into a definitive agreement under which Adaptimmune will combine with TCR² in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms. As a result, and following the closing of the transaction, it is anticipated that the combined company’s cash runway will extend into 2026. Read more here.